In the grimdark future of the 41st millennium, there is only war, and you can fight your way through it, beginning with the ...

A young parolee brings unforeseen magic to a forlorn little town in “The Spitfire Grill,” running at Ross Valley Players through Feb. 23.

Charlotte Wood’s novel, a Booker Prize finalist, follows an atheist whose mysterious path led her to live among nuns in a ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.

Don’t we have legislation in place to prevent foreign electoral interference? Because now would be a good time to press that ...

A new memoir by the tech mogul recounts a boyhood steeped in old-fashioned, analog pastimes as well as precocious feats of coding.

In a new memoir, Hanif Kureishi reflects on a life transformed since he lost the use of his arms and legs.

Imagine molding your perfect mate. That’s what happens in “Blob: A Love Story,” the debut novel from Maggie Su, whose ...